Mick Cooper
Recent Quotes
"Commercial launch of AMBS' LymPro remains on track for H2/14."
—
Mick Cooper, Edison Investment Research
(8/18/14)
more >
"A good price point for OMER's Omidria at launch and EU approval would maintain momentum through 2014."
—
Mick Cooper, Edison Investment Research
(7/3/14)
more >
"AMBS has a transformative year ahead and a diverse pipeline of promising products."
—
Mick Cooper, Edison Investment Research
(5/14/14)
more >
Due to permission requirements, not all quotes are shown.
